NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Devices · USD

Boston Scientific Corporation (BSX) Stock Analysis

Boston Scientific Corporation (BSX) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

BSX

$47.80

+$0.85 (+1.81%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BSX with… →

BSX Key Statistics

As of Sep 4, 2026
Trading
Open
$46.92
Previous Close
$46.95
Day's Range
46.83–48.06
52-Week Range
42.20–109.50
Volume
15.50M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.57
Valuation
Market Cap
$69.27B
P/E Ratio
19.35
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.92
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.65
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.30
EPS (ttm)Profit attributable to each share over the last twelve months.
2.47
Financials (FY)
Revenue (FY)
$20.07B+19.87%
Net Income (FY)
$2.90B+56.31%
Profit marginThe share of revenue left as profit after all costs and taxes.
17.50%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.45B
1-Year Return
−55.45%
Dividend and dates
Earnings Date
October 28, 2026
Avg Volume
19.84M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BSX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−49.87%
2025+6.75%
2024+54.51%
2023+24.94%
2022+8.92%
2021+18.16%
2020−20.50%
2019+27.96%
2018+42.56%
2017+14.61%
2016 (partial year)−9.42%

As of September 4, 2026.

BSX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$20.07B$2.90B14.4%
2024$16.75B$1.85B11.1%
2023$14.24B$1.59B11.2%
2022$12.68B$698.00M5.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$20.07B$13.85B$3.97B$2.90B14.4%
2024$16.75B$11.49B$3.00B$1.85B11.1%
2023$14.24B$9.90B$2.42B$1.59B11.2%
2022$12.68B$8.73B$2.03B$698.00M5.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BSX Valuation vs Medical Devices Median

Median of 151 stocks
MetricBSXMedical Devices medianvs median
P/E19.3526.8028% below
P/S ratio3.302.9811% above
Profit margin17.50%−1.69%19.2 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Boston Scientific Corporation (BSX) carries a market capitalisation of $69.27B. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 59,000.

BSX last closed at $47.80 on September 4, 2026. That is +$0.85 (+1.81%) against the previous close. The 52-week range on file runs from $42.20 to $109.50. The latest close sits 13.27% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $20.07B. Against the prior fiscal year total of $16.75B, that is a change of +19.87%. Net income for the same year was $2.90B. That is +56.31% against the prior fiscal year. The reported profit margin is 17.5%. That is 19.2 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to 2.47.

Across the 4 fiscal years on file, revenue moves from $12.68B in 2022 to $20.07B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 19.35 times earnings. That is 27.8% below the Medical Devices median of 26.8. The forward P/E on file is 13.92. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.65. The price-to-sales ratio is 3.3. On price-to-sales that is 10.86% above the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −55.45%. Measured over 10 years, that is +7.02% a year compounded. The reported beta is 0.57. Daily returns over the trailing 10 years annualize to a volatility of 27.64%.

Growth & Income

The record shows no dividend for BSX.

The strongest complete calendar year on file is 2024 at +54.51%; the weakest is 2020 at −20.50%. Of the 9 complete calendar years on file, 8 finished higher. So far in 2026 the price is −49.87%.

Peer Comparison

Boston Scientific Corporation (BSX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Boston Scientific Corporation BSX $69.27B 19.4
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Boston Scientific Corporation trades at a P/E of 19.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B

 GEHC

GE HealthCare Technologies Inc.

$31.10B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Visit website →